Bluebirdbio stock.

For perspective, our theme on Gene Editing stocks remains down by 37% year-to-date. However, there was some positive news for the sector last week, after gene editing player Bluebird Bio BLUE 0.0% ...Bluebird bio's treatment for a rare blood disorder received backing from advisers to the U.S. Food and Drug Administration on Friday, in a vote of confidence in gene therapies and bolstering the ...Jul 12, 2023 · Curious what investors think of the latest price action? When the Bank of America upgraded its rating for Bluebird, the stock shot up from $3.13 to a high of $3.93, and today it closed at $3.51. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.The past several years have been brutal for biotech company Bluebird bio (BLUE 1.34%).Shares of the gene-editing specialist are down by 85% since early 2020 as it has had to deal with clinical and ...

Earnings for bluebird bio are expected to decrease in the coming year, from ($1.81) to ($1.84) per share. bluebird bio has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off prior year's report dates. Read More.

Real time Bluebird Bio (BLUE) stock price quote, stock graph, news & analysis.[relinking] Home History Owners Mission How It Works How It Makes Money A Brief History of bluebird bio, Inc. (BLUE) bluebird bio, Inc. is a biotechnology company that focuses on developing gene therapies for severe genetic diseases and cancer. The company was founded in 1992 by a group of former employees of Genzyme, a biotechnology company …

SOMERVILLE, Mass.--(BUSINESS WIRE)--Aug. 8, 2023-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the second quarter ended June 30, 2023, including recent commercial and operational progress, and regulatory updates.Investors are ditching this gene therapy stock en masse, for good reason. The share price of bluebird bio ( BLUE -0.91%) is down a staggering 70% over the past year. The company has encountered ...A high-level overview of bluebird bio, Inc. (BLUE) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Nov 24, 2023 · The low in the last 52 weeks of bluebird bio stock was 2.52. According to the current price, bluebird bio is 155.56% away from the 52-week low. What was the 52-week high for bluebird bio stock? Complete bluebird bio Inc. stock information by Barron's. View real-time BLUE stock price and news, along with industry-best analysis.

1. bluebird bio. Many biotech stocks soared last year. Not bluebird bio (BLUE-5.14%).Its shares plunged nearly 50%. While that certainly wasn't good for Bluebird shareholders, I think it makes the ...

18 thg 10, 2019 ... bluebird bio. 994 views · 4 years ago ...more. Alliance for Regenerative ... Bluebird stock pops after FDA approves its gene therapy drug. Yahoo ...

bluebird bio Submits Biologics License Application (BLA) to FDA for ...Dec 1, 2023 · Who is on bluebird bio's Insider Roster? The list of insiders at bluebird bio includes Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Nick Leschly, Richard A Colvin, Thomas J Klima, and William D Baird III. Learn more on insiders at BLUE. 7 thg 11, 2023 ... Sarah Alspach of bluebird bio shares valuable guidance for aspiring comms leaders. Her work has earned her a spot as one of Ragan's 2023 Game ...Nov 7, 2023 · Bluebird Bio ( BLUE 11.52%) had quite a ride with their stock on Tuesday. Following the gene-editing specialist's release of its latest quarterly results, its shares climbed to a more than 7% gain ... Shares of the commercial-stage gene therapy company bluebird bio ( BLUE 3.55%) are having a strong session Wednesday. The biotech's stock was up by a noteworthy 18.8% on heavy volume as of 10:41 a ...

Many gene-editing stocks have taken a hit in the past year, but analysts at Strategic Market Research still expect the genome-editing market to grow 17.3% annually and reach $21.3 billion by 2030.Shares of the commercial-stage gene therapy company bluebird bio (BLUE 11.52%) are having a strong session Wednesday. The biotech's stock was up by a noteworthy 18.8% on heavy volume as of 10:41 a ...Summary. bluebird works as a biotech company developing curative gene therapies to save lives. Concerns over its cash runway and clinical trials are overblown, with the stock near all-time lows ...Get the latest bluebird bio, Inc. (BLUE) stock news and headlines to help you in your trading and investing decisions.Bluebird Bio. Market Cap. $425M. Today's Change. Current Price. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ from The Motley Fool’s ...The low in the last 52 weeks of bluebird bio stock was 2.52. According to the current price, bluebird bio is 155.56% away from the 52-week low. What was the 52-week high for bluebird bio stock?bluebird bio Inc (BLUE) stock is higher by 0.26% while the S&P 500 is down -0.11% as of 11:47 AM on Thursday, Nov 30. BLUE has risen $0.01 from the previous closing price of $3.86 on volume of 1,460,801 shares. Over the past year the S&P 500 is up 14.86% while BLUE is down -49.41%. BLUE lost -$0.74 per share in the over the last 12 …

Bluebird Bio BLUE Pre PDUFA Summary 04Dec2023Thank you for watching this video If you like it please like the video and subscribe to my page. Please excuse t...Bluebird bio's blood disorder treatment demonstrates "clinically meaningful" benefit in patients, staff reviewers at the U.S. Food and Drug Administration said in briefing documents published on ...

Read Our Latest Stock Report on BLUE. bluebird bio Stock Performance. Shares of NASDAQ:BLUE opened at $4.26 on Friday. bluebird bio, Inc. has a 1 year low of $2.52 and a 1 year high of $8.58. The ...Bluebird Bio (BLUE) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.54 per share. This compares to loss of $1.66 per share a year ago.Find the latest historical data for bluebird bio, Inc. Common Stock (BLUE) at Nasdaq.com.Here are three top biotech stocks with major catalysts in December. Editas Medicine ( EDIT ): EDIT will release key clinical data on its sickle cell treatment on Dec. 11. Bluebird Bio ( BLUE ): It ...Mar 7, 2022 · Specifically, the biotech's stock is down by 11% as of 12:56 p.m. ET on Monday. Bluebird's shares are retreating today in response to two key issues: First, the company's 2021 fourth-quarter and ... A $3M gene therapy: Bluebird bio breaks its own pricing record with FDA approval of Skysona. The $3 million price tag on bluebird bio's newly approved drug reflects “the clinical benefit ...Earnings for bluebird bio are expected to decrease in the coming year, from ($1.81) to ($1.84) per share. bluebird bio has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off prior year's report dates. Read More.bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.Jun 29, 2023 · Bluebird Bio. Market Cap. $425M. Today's Change. Current Price. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ from The Motley Fool’s ...

bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How. bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its …

SOMERVILLE, Mass., January 19, 2023--bluebird bio, Inc. (Nasdaq: BLUE) ("bluebird") today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a ...

May 21, 2020 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--May 18, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) today announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to ... Bluebird Bio has two advantages over CRISPR Therapeutics that could allow its stock to soar fivefold faster. First, Bluebird is much smaller -- small-cap stocks tend to be capable of more ...Pgiam/iStock via Getty Images. bluebird bio ( NASDAQ: BLUE) added ~8% pre-market Wednesday after Bank of America upgraded the stock to Buy from Neutral, citing a potential FDA approval for its new ...bluebird bio, Inc. BLUE shares gained 14% to $3.59 in pre-market trading. B of A Securities upgraded bluebird bio from Neutral to Buy and raised the price target from $6 to $10.bluebird bio. bluebird bio received FDA accelerated approval for SKYSONA® (elivaldogene autotemcel) gene therapy for early, active cerebral adrenoleukodystrophy (CALD). SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and fatal neurodegenerative disease.Get the latest bluebird bio Inc (BLUE) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment …Nov 7, 2023 · bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. Bluebird Bio has a market capitalization of around $425 million at the moment, so this small-cap biotech stock could see a significant increase in its share …Target values for the price of one bluebird bio share for Nov 2025. The weighted average target price per bluebird bio share in Nov 2025 is: 8.72. In Nov, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 19.746% volatility is expected. Pessimistic target level: 7.95. Optimistic target level: 9.91.Bluebird Bio Inc (NASDAQ: BLUE) shares are trading lower Monday. The stock initially surged in premarket trading following the U.S. Food and Drug Administration's accelerated approval of ...bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders. The company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. Shares of Bluebird Bio (BLUE-0.78%) were crashing 23.3% lower as of 12:18 p.m. EDT on Monday. The big decline came after the company announced two negative developments in its second-quarter update.

Target values for the price of one bluebird bio share for Nov 2025. The weighted average target price per bluebird bio share in Nov 2025 is: 8.72. In Nov, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 19.746% volatility is expected. Pessimistic target level: 7.95. Optimistic target level: [email protected]. Investor Contacts. Courtney O’Leary. Investor Relations (978) 621-7347. [email protected]. stock quote stock sub menu. Stock ... 12 thg 7, 2023 ... Concerns over its cash runway and clinical trials are overblown, with the stock near all-time lows. ... bluebird bio's product pipeline (www.bluebird bio, Inc. Common Stock (BLUE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Instagram:https://instagram. get funded to tradevanguard cyber security etfprice 1943 steel pennynasdaq exel Jul 19, 2023 · Pgiam/iStock via Getty Images. bluebird bio ( NASDAQ: BLUE) added ~8% pre-market Wednesday after Bank of America upgraded the stock to Buy from Neutral, citing a potential FDA approval for its new ... td bank shares valuebest program to trade stocks bluebird bio, Inc. (BLUE) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 4.2600 +0.4400 (+11.52%) At close: 04:00PM EST 4.3300 +0.07 (+1.64%) … qqq fees Bluebird Bio (BLUE 11.52%) and CRISPR Therapeutics (CRSP 2.88%) are two rising biotechs that specialize in gene-editing therapies to treat rare genetic blood disorders and cancer.In addition, bluebird bio, Inc. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style).Dec 1, 2023 · bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.